ulrichINJECT CT Motion (XD 8000)

K251295 · Ulrich GmbH & Co. KG · IZQ · Nov 7, 2025 · Cardiovascular

Device Facts

Record IDK251295
Device NameulrichINJECT CT Motion (XD 8000)
ApplicantUlrich GmbH & Co. KG
Product CodeIZQ · Cardiovascular
Decision DateNov 7, 2025
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 870.1650
Device ClassClass 2

Intended Use

ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. ulrichINJECT CT motion is specifically indicated for use in CT procedures for the delivery of the following contrast media: - Iohexol Injection in single-dose (SD) container or Imaging Bulk Package (IBP) - Iodixanol Injection in SD container - Iopamidol Injection in IBP Pump tubing – flex can be used with a maximum of 36 bottles of contrast media or a maximum time of twenty-four (24) hours, whichever comes first. Use time expiration per SD container is a maximum of four (4) hours from initial puncture, unless otherwise stated by the contrast media labeling. Use time expiration per IBP is limited to a maximum time stated by the specific contrast media labeling. Use time expiration per saline container is a maximum of twenty four (24) hours from initial puncture. Spike for CT disposable is for single-bottle use only and must be discarded with the media container. The maximum time usage for the Spike for CT is twenty four (24) hours, or the maximum use time for the contrast media container indicated for use with ulrichINJECT CT motion, whichever comes first. The Patient tubing must be discarded after each patient procedure. SYNCOpen is indicated for the specific purpose of allowing an injector to interface with a CT scanner. RIS/PACS is indicated for the specific purpose of allowing an injector to interface with a Radiological Information System (RIS) and a Picture Archiving and Communications System (PACS). ulrichINJECT CT motion is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast media.

Device Story

Syringeless contrast media management system; utilizes peristaltic pump to deliver contrast media and saline from containers to patient via disposable tubing set (spike, pump tubing-flex, patient tubing). System includes injector head, touch terminal, and mounting options (pedestal/ceiling). Hardware/software controls include ultrasound air detectors, pressure sensors, and check valves to prevent backflow/contamination. Integrates with CT scanners (SYNCOpen) and RIS/PACS for workflow automation. Operated by trained healthcare professionals in radiological suites; provides controlled, automated delivery to improve diagnostic imaging accuracy. System prevents disposable reuse via software locks. Benefits include reduced manual handling, contamination control, and precise contrast administration.

Clinical Evidence

Bench testing only. Includes microbial ingress studies (24-hour/36-bottle limit), chemical compatibility (Iopamidol IBP), extractables/leachables, biocompatibility (ISO 10993-1), electrical safety (IEC 60601-1), and usability/human factors evaluations. No clinical data presented.

Technological Characteristics

Syringeless peristaltic pump system. Materials: PVC/PUR tubing. Connectivity: SYNCOpen (CT interface), RIS/PACS. Power: 100-240V AC, battery-powered. Sterilization: EtO (ISO 11135). Air detection: Ultrasound (0.05 mL limit). Occlusion detection: Piezo-resistive sensor (246 PSI limit). Software: Multi-layered safety stops, disposable reuse prevention.

Indications for Use

Indicated for human subjects undergoing CT diagnostic examinations requiring controlled, automatic venous administration of contrast media (Iohexol, Iodixanol, Iopamidol) and saline. Used by trained healthcare professionals in licensed radiological facilities.

Regulatory Classification

Special Controls

*Classification.* Class II (special controls). The device, when it is a non-patient contacting balloon inflation syringe intended only to inflate/deflate balloon catheters and monitor pressure within the balloon, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} FDA U.S. FOOD & DRUG ADMINISTRATION November 7, 2025 ulrich GmbH & Co. KG % Rita King Chief Executive Officer MethodSense, Inc. 1 Copley Pkwy Suite 130 Morrisville, North Carolina 27560 Re: K251295 Trade/Device Name: ulrichINJECT CT Motion (XD 8000) Regulation Number: 21 CFR 870.1650 Regulation Name: Angiographic injector and syringe Regulatory Class: Class II Product Code: IZQ Dated: October 6, 2025 Received: October 6, 2025 Dear Rita King: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K251295 - Rita King Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K251295 - Rita King Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Kyran R. Gibson -S for Shruti Mistry Assistant Director DHT3C: Division of Drug Delivery and General Hospital Devices, and Human Factors OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Indications for Use Form Approved: OMB No. 0910-0120 Expiration Date: 07/31/2026 See PRA Statement below. 510(k) Number (if known) K251295 Device Name ulrichINJECT CT Motion (XD 8000) Indications for Use (Describe) ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. ulrichINJECT CT motion is specifically indicated for use in CT procedures for the delivery of the following contrast media: - Iohexol Injection in single-dose (SD) container or Imaging Bulk Package (IBP) - Iodixanol Injection in SD container - Iopamidol Injection in IBP Pump tubing – flex can be used with a maximum of 36 bottles of contrast media or a maximum time of twenty-four (24) hours, whichever comes first. Use time expiration per SD container is a maximum of four (4) hours from initial puncture, unless otherwise stated by the contrast media labeling. Use time expiration per IBP is limited to a maximum time stated by the specific contrast media labeling. Use time expiration per saline container is a maximum of twenty four (24) hours from initial puncture. Spike for CT disposable is for single-bottle use only and must be discarded with the media container. The maximum time usage for the Spike for CT is twenty four (24) hours, or the maximum use time for the contrast media container indicated for use with ulrichINJECT CT motion, whichever comes first. The Patient tubing must be discarded after each patient procedure. SYNCOpen is indicated for the specific purpose of allowing an injector to interface with a CT scanner. RIS/PACS is indicated for the specific purpose of allowing an injector to interface with a Radiological Information System (RIS) and a Picture Archiving and Communications System (PACS). ulrichINJECT CT motion is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast media. Type of Use (Select one or both, as applicable) ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) CONTINUE ON A SEPARATE PAGE IF NEEDED. FORM FDA 3881 (8/23) Page 1 of 2 PSC Publishing Services (301) 443-6740 {4} This section applies only to requirements of the Paperwork Reduction Act of 1995. **DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.** The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." FORM FDA 3881 (8/23) Page 2 of 2 {5} ulrichINJECT CT motion Traditional 510(k) Page 1 of 10 Summary of 510(k) K251295 ulrich GmbH & Co. KG This 510(k) Summary is in conformance with 21CFR 807.92 Submitter: ulrich GmbH & Co. KG Buchbrunnenweg 12 89081 Ulm Germany Primary Contact: Rita King CEO MethodSense, Inc. Company Contact: Sven Erdmann Vice President of Technology – Regulatory Device Name and Classification Trade Name: ulrichINJECT CT motion Common Name: Contrast Media Management System Classification: Class II Regulation Number: 21 CFR 870.1650, Angiographic Injector and Syringe Classification Panel: Cardiovascular Panel Product Code: IZQ Predicate Device: | Trade Name | ulrichINJECT CT motion | | --- | --- | | Common Name | Contrast Media Management System | | 510(k) Submitter / Holder | ulrich GmbH & Co. KG | | 510(k) Number | K210541 | | Classification | Class II | | Regulation Number | 21 CFR 870.1650, Angiographic Injector and Syringe | | Classification Panel | Cardiovascular Panel | | Product Code | IZQ | The predicate device has not been subject to a design-related recall. Device Description ulrichINJECT CT motion is a syringeless contrast media management system that is designed for the controlled, automatic administration, on the venous side, of contrast media and saline, to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. The ulrichINJECT CT motion system consists of a terminal, injector, and tubing system. The tubing system is the only component that comes in contact with the patient and has indirect contact with the blood path of a patient for a limited duration (<24 hours). The tubing system consists of the following three (3) components: - Spike for CT (CM/NaCl); - Pump tubing – flex; and - Patient Tubing. ulrichINJECT CT motion uses a peristaltic pump as part of the injector which is designed to transport the media fluid through the tubing system (spikes, pump tubing – flex, and patient tubing). ulrichINJECT CT motion is intended to be used with the following components that are not supplied with the system: - Saline containers, {6} - Single-dose contrast media containers, - Imaging Bulk Package (IBP) contrast media containers, and - Cannula. ulrichINJECT CT motion is equipped with multiple hardware and software controls that work together for the safe operation of the intended use of the system. Controls include air detectors to detect the presence of air in the tubing system without direct contact with the medium, pressure controls to manage and regulate pressure inside the tubing system, and check valves to prevent backflow of media and avoid retrograde contamination. The ulrichINJECT CT motion is provided in two versions: - Mobile pedestal version - Ceiling version The mobile pedestal version consists of the injector head and the injector base with rechargeable battery. The ceiling version consists of the injector head, a fixed-height arm, and a movable arm. ## Indications for Use ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. ulrichINJECT CT motion is specifically indicated for use in CT procedures for the delivery of the following contrast media: - Iohexol Injection in single-dose (SD) container or Imaging Bulk Package (IBP) - Iodixanol Injection in SD container - Iopamidol Injection in IBP Pump tubing – flex can be used with a maximum of 36 bottles of contrast media or a maximum time of twenty-four (24) hours, whichever comes first. Use time expiration per SD container is a maximum of four (4) hours from initial puncture, unless otherwise stated by the contrast media labeling. Use time expiration per IBP is limited to a maximum time stated by the specific contrast media labeling. Use time expiration per saline container is a maximum of twenty four (24) hours from initial puncture. Spike for CT disposable is for single-bottle use only and must be discarded with the media container. The maximum time usage for the Spike for CT is twenty four (24) hours, or the maximum use time for the contrast media container indicated for use with ulrichINJECT CT motion, whichever comes first. The Patient tubing must be discarded after each patient procedure. SYNClopen is indicated for the specific purpose of allowing an injector to interface with a CT scanner. RIS/PACS is indicated for the specific purpose of allowing an injector to interface with a Radiological Information System (RIS) and a Picture Archiving and Communications System (PACS). ulrichINJECT CT motion is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast media. ## Predicate Device Comparison ulrichINJECT CT motion is substantially equivalent to the ulrichINJECT CT motion (K210541) by ulrich GmbH & Co. KG that is currently on the market. ulrichINJECT CT motion Traditional 510(k) Page 2 of 10 {7} Comparative Analysis of the ulrichINJECT CT motion to the Predicate Device | Item | Subject Device ulrichINJECT CT motion (K251295) | Predicate Device ulrichINJECT CT motion (K210541) | Comparison | | --- | --- | --- | --- | | Intended Use | ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. | ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. | Same | | Indications for Use | ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. ulrichINJECT CT motion is specifically indicated for use in CT procedures for the delivery of the following contrast media: • Iohexol Injection in single-dose (SD) container or Imaging Bulk Package (IBP) • Iodixanol Injection in SD container • lopamidol Injection in IBP Pump tubing – flex can be used with a maximum of 36 bottles of contrast media or a maximum time of twenty-four (24) hours, whichever comes first. Use time expiration per SD container is a maximum of four (4) hours from initial puncture, unless otherwise stated by the contrast media labeling. Use time expiration per IBP is limited to a maximum time stated by the specific contrast media labeling. Use time expiration per saline container is a maximum of twenty four (24) hours from initial puncture. | ulrichINJECT CT motion is a contrast media management system that is indicated for the controlled, automatic administration, on the venous side, of contrast media and saline (NaCl), to human subjects undergoing diagnostic examinations in computed tomography (CT) applications. ulrichINJECT CT motion is specifically indicated for use in CT procedures for the delivery of Omnipaque™ (Iohexol) Injection, solution - GE Healthcare Inc. contrast media as supplied in Imaging Bulk Packages (IBP), Omnipaque™ (Iohexol) Injection, solution - GE Healthcare Inc., and Visipaque™ (iodixanol) Injection - GE Healthcare Inc. contrast media as supplied in single dose bottles. Pump tubing-flex is used for a maximum time of twenty four (24) hours. When used with Omnipaque™ IBP, Omnipaque™ single dose bottles, or Visipaque™ single dose bottles, a maximum of 19 bottles of contrast media can be used or maximum time of twenty four (24) hours of Pump tubing-flex, or whichever comes first. Time per contrast media or saline container depends on each contrast media's or saline's use time expiration with a maximum of eight (8) hours per contrast media or saline container. Spike for CT disposable is for single-bottle use only and must be discarded with the media container. The Patient tubing must be discarded | Different - This difference does not change the intended use of the device. The safety and effectiveness of the ulrichINJECT CT motion has been confirmed through chemical compatibility and contamination control testing. | ulrichINJECT CT motion Traditional 510(k) Page 3 of 10 {8} ulrichINJECT CT motion Traditional 510(k) Page 4 of 10 | Item | Subject Device ulrichINJECT CT motion (K251295) | Predicate Device ulrichINJECT CT motion (K210541) | Comparison | | --- | --- | --- | --- | | | Spike for CT disposable is for single-bottle use only and must be discarded with the media container. The maximum time usage for the Spike for CT is twenty four (24) hours, or the maximum use time for the contrast media container indicated for use with ulrichINJECT CT motion, whichever comes first. The Patient tubing must be discarded after each patient. SYNCopen is indicated for the specific purpose of allowing an injector to interface with a CT scanner. RIS/PACS is indicated for the specific purpose of allowing an injector to interface with a Radiological Information System (RIS) and a Picture Archiving and Communications System (PACS). ulrichINJECT CT motion is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast media. | after each patient procedure. SYNCopen is indicated for the specific purpose of allowing an injector to interface with a CT scanner. RIS/PACS is indicated for the specific purpose of allowing an injector to interface with a Radiological Information System (RIS) and a Picture Archiving and Communication System (PACS). ulrichINJECT CT motion is to be used only by and under quasi-continuous supervision of trained healthcare professionals in an appropriate licensed healthcare facility, in a room designated for radiological procedures that involve intravascular administration of contrast agent. | | | System | Injector Head Touch Terminal | Injector Head Touch Terminal | Same | | Accessories | Injector Base (pedestal) Ceiling Mount with moveable arm Contrast Media Housing with Heater Media label reader | Injector Base (pedestal)Wall Mount with moveable arm Ceiling Mount with moveable arm Contrast Media Housing with Heater | Different - This difference does not change the intended use of the device. The safety and effectiveness of the ulrichINJECT CT motion has been confirmed through verification and validation testing. | | Disposables | ulrichINJECT CT Motion Pump Tubing-flex Patient Tubing for Pump Tubing-flex ulrichINJECT CT Motion Spike for CT | ulrichINJECT CT Motion Pump Tubing-flex Patient Tubing for Pump Tubing-flex ulrichINJECT CT Motion Spike for CT | Same | | Weight | Injector (pedestal version): Approx. 80 kg Injector (ceiling version): Approx. 40 kg Terminal: Approx. 3 kg | Injector (pedestal version): Approx. 80 kg Injector (ceiling and wall mount version): Approx. 40 kg Terminal: Approx. 3 kg | Same | {9} ulrichINJECT CT motion Traditional 510(k) Page 5 of 10 | Item | Subject Device ulrichINJECT CT motion (K251295) | Predicate Device ulrichINJECT CT motion (K210541) | Comparison | | --- | --- | --- | --- | | Dimensions | Injector (pedestal version): 64.5 x 64.5 x 144.5 cm Injector (ceiling version): Depends on the system selected and the length of the fixed height arm Terminal: 31 x 27.5 x 17 cm | Injector (pedestal version and wall mount version): 64.5 x 64.5 x 144.5 cm Injector (ceiling version): Depends on the system selected and the length of the fixed height arm Terminal: 31 x 27.5 x 17 cm | Same | | Power Requirement | Rated Voltage: 100 to 240 V AC Rated Current: 1.6 A Rated Frequency: 50/60Hz | Rated Voltage: 100 to 240 V AC Rated Current: 1.6 A Rated Frequency: 50/60Hz | Same | | Battery | Lead gel battery or Li-Ion battery | Lead gel battery or Li-Ion battery | Same | | Display Type | Color LCD Terminal with touch screen | Color LCD Terminal with touch screen | Same | | Syringeless system | Yes | Yes | Same | | Remote Operation | Yes, via the Touch Terminal | Yes, via the Touch Terminal | Same | | Single Patient Use Disposable | Patient Tubing for Pump Tubing-flex | Patient Tubing for Pump Tubing-flex | Same | | Designed to Prevent Reuse of Disposables | Yes – via the use of software controls | Yes – via the use of software controls | Same | | Rotary peristaltic pump | Yes | Yes | Same | | Used to administer contrast media and saline | Yes | Yes | Same | | Disposable uses spikes to spike media container | Yes | Yes | Same | | Safety Stop Mechanism | Multi-layered software stops; Used Patient Tubing detector and Pump Tubing-flex detector | Multi-layered software stops; Used Patient Tubing detector and Pump Tubing-flex detector | Same | | Volume Remaining Readout | Yes, displayed on control unit if programmed volume is higher than remaining volume A traffic light feature is included to better indicate remaining media volume on the GUI. | Yes, displayed on control unit if programmed volume is higher than remaining volume | Different - This difference does not change the intended use of the device. The safety and effectiveness of the ulrichINJECT CT motion has been confirmed through verification and validation testing. | | Programmable Pressure Limit | Yes, 195 PSI; user-programmable or automatic | Yes, 195 PSI; user-programmable or automatic | Same | {10} ulrichINJECT CT motion Traditional 510(k) Page 6 of 10 | Item | Subject Device ulrichINJECT CT motion (K251295) | Predicate Device ulrichINJECT CT motion (K210541) | Comparison | | --- | --- | --- | --- | | Injector-Scanner Interface | SYNCOpen functionality allows start of the injector and CT scanner simultaneously and communicates information from the CT motion to the CT scanner. | SYNCOpen functionality allows start of the injector and CT scanner simultaneously and communicates information from the CT motion to the CT scanner. | Same | | Injection Capabilities | 40 phases per protocol | 40 phases per protocol | Same | | Injection Rates for Contrast Media | 0.1 mL/s to 10.0 mL/s | 0.1 mL/s to 10.0 mL/s | Same | | Injection Rates for Saline | 0.1 mL/s to 10.0 mL/s | 0.1 mL/s to 10.0 mL/s | Same | | Injection Volume per Injection | 1 to 200 mL max volume of contrast media per patient with a max of 400 mL total media (contrast and saline) per patient | 1 to 200 mL max volume of contrast media per patient with a max of 400 mL total media (contrast and saline) per patient | Same | | Flow Rate and Volume Accuracy | 10-200 mL of contrast media with volume accuracy of ± 5% Flow rate accuracy of ± 5% | 10-200 mL of contrast media with volume accuracy of ± 5% Flow rate accuracy of ± 5% | Same | | Contrast Media Container Volume | 100mL – 500mL | 100mL – 500mL | Same | | Compatible Contrast Media | lohexol Injection in IBP lohexol Injection in SD container lodixanol Injection in SD container lopamidol Injection in IBP | OMNIPAQUE™ (lohexol) IBP OMNIPAQUE™ (lohexol) single dose VISIPAQUE™ (lodixanol) single dose | Different - This difference does not change the intended use of the device. The safety and effectiveness of the ulrichINJECT CT motion has been confirmed through chemical compatibility testing. | | Saline Flush | Yes | Yes | Same | | Needle Size | 14-24 G | 14-24 G | Same | | Injection Pause | Programmable - 0 sec to 999 sec in 1 sec increments | Programmable - 0 sec to 999 sec in 1 sec increments | Same | | Injection Protocol Storage | Yes | Yes | Same | | Priming/Venting Rate | 2 mL/s (manual) | 2 mL/s (manual) | Same | | Air Detection Principle | Ultrasound | Ultrasound | Same | | Technical Detection Limit of air in tubing | 0.05 mL | 0.05 mL | Same | {11} ulrichINJECT CT motion Traditional 510(k) Page 7 of 10 | Item | Subject Device ulrichINJECT CT motion (K251295) | Predicate Device ulrichINJECT CT motion (K210541) | Comparison | | --- | --- | --- | --- | | Air Detector Alarm Limit | 1 mL | 1 mL | Same | | Occlusion Detection Principle | Fail safe piezo-resistive pressure sensor | Fail safe piezo-resistive pressure sensor | Same | | Occlusion Detection Alarm Limit | 246 PSI | 246 PSI | Same | | Time Limit for Disposables | 24 hours for ulrichINJECT CT Motion Pump Tubing-flex 12 hours for Patient Tubing for Pump Tubing-flex 24 hours for ulrichINJECT CT Motion Spike for CT | 24 hours for ulrichINJECT CT Motion Pump Tubing-flex 12 hours for Patient Tubing for Pump Tubing-flex 8 hours for ulrichINJECT CT Motion Spike for CT | Same | | Package Sterile | Yes | Yes | Same | | Sterilization Method | Ethylene Oxide (EtO) | Ethylene Oxide (EtO) | Same | | Packaging Configuration | Tyvek lid covering polystyrole tray | Tyvek lid covering polystyrole tray | Same | | Patient Tubing Components | Patient Tubing Two Patient Luer Connectors with safety caps Two check valves | Patient Tubing Two Patient Luer Connectors with safety caps Two check valves | Same | | Safety Feature Against Re-use | Yes, via software controls | Yes, via software controls | Same | | Pump-Tubing Flex Components | Contrast media lines x2 Saline Line W-piece Pressure sensor unit with integrated particle filter Check valve Swabable valves x 4 | Contrast media lines x2 Saline Line W-piece Pressure sensor unit with integrated particle filter Check valve Swabable valves x 4 | Same | | Contrast Media Line Tubing Material | PVC / PUR | PVC / PUR | Same | | Saline Line Tubing Material | PVC / PUR | PVC / PUR | Same | | Spike Size | PVC / PUR | PVC / PUR | Same | | Safety Feature Against Re-Use | Yes, via software controls | Yes, via software controls | Same | {12} ulrichINJECT CT motion Traditional 510(k) Page 8 of 10 # Non-Clinical Testing ulrichINJECT CT motion system and software were validated in accordance with a Verification & Validation plan to ensure conformance with established performance criteria. # Software Software verification and validation was performed as part of K171392, K192872, and K210541 and has been repeated for the software updates made as part of this submission. # Cybersecurity ulrich performed cybersecurity testing for the ulrichINJECT CT motion system in accordance with FDA guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (September 27, 2023). # Electromagnetic Compatibility / Electrical Safety Testing Electromagnetic compatibility and electrical safety testing was performed in accordance with the following standard: - IEC 60601-1:2005, AMD 1:2012, AMD 2:2020 and under compliance with the FDA recognized standard ANSI AAMI ES60601-1:2005/(R)2012 & A1:2012, C1:2009/(R)2012 & A2:2010/(R)2012 (Cons. Text) [Incl. AMD2:2021] Medical electrical equipment - Part 1: General requirements for basic safety and essential performance (IEC 60601-1:2005, MOD) [Including Amendment 2 (2021)]. # Sterilization Validation The ulrichINJECT CT motion tubing system is ethylene oxide (EtO) sterilized and was validated in accordance with ISO 11135:2014 to a sterility assurance level of $10^{-6}$ as part of K171392, K192872, and K210541. # Shelf Life and Transport Validation Real-time aging studies were performed wherein the ulrichINJECT CT motion tubing system was sterilized and its packaging was validated. ulrich performed transport validation on the ulrichINJECT CT motion tubing system, injector, and terminal. # Chemical Compatibility In addition to Chemical Compatibility testing performed in support of K171392 and K192872, additional Chemical Compatibility testing was performed to support the material compatibility of the ulrichINJECT CT motion tubing system with lopamidol Injection in IBPs. # Contamination Control and Rinsing In addition to contamination control testing performed in support of K171392 and K192872, ulrich performed the following Contamination Control Studies for the ulrichINJECT CT motion: - A microbial ingress study demonstrated the ability of the ulrichINJECT CT motion system to prevent the ingress of microorganisms during use up to 24 hours or a maximum of 36 bottles. {13} ulrichINJECT CT motion Traditional 510(k) Page 9 of 10 # Biocompatibility The ulrichINJECT CT motion tubing system indirect patient contact materials were verified in accordance with the following standards as part of K171392 and K192872: - ISO 10993-1, Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process. Verification results indicated that the materials comply with the standard. # Reprocessing Cleaning and disinfection validation testing was completed in accordance with FDA guidance Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling and the following standards: - ANSI/AAMI ST98:2022, - AAMI TIR30:2011/(R)2016, - AAMI TIR12:2020/(R)2023, and - ISO 17664-2:2021 Testing was performed to demonstrate the compatibility and durability of the ulrichINJECT CT motion with cleaning agents and disinfectants. # Performance – Bench The ulrichINJECT CT motion tubing system was tested for performance and verified in accordance with the following standard as part of K171392: - ISO 8536-4:2010, Infusion equipment for medical use - Part 4: Infusion sets for single use, gravity feed ulrichINJECT CT motion tubing system is not a gravity feed device; therefore, only the applicable requirements from ISO 8536-4 were tested. Testing was also performed as part of K192872 to confirm that mixing of contrast media will not occur. Test and verification results indicated that the ulrichINJECT CT motion tubing system conforms to its predetermined specifications and the applicable standards. # Extractables and Simulation Simulation testing was performed for leachable compounds with lopamidol as a part of this submission. Additionally, testing was previously performed for extractables and simulation testing for leachable compounds with lohexol and lodixanol as a part of K192872. # Human Factors / Usability In addition to usability studies performed as part of K171392, usability evaluations, including a usability study, were performed as part of this submission to confirm that the updated ulrichINJECT CT motion system with additional software options remains safe and effective for use by the intended user population. # Conclusion In conclusion, the intended use of the ulrichINJECT CT motion is the same as that of the predicate device (K210541). The differences between the predicate and subject device do not raise any new or {14} different questions of safety and effectiveness. The non-clinical testing has demonstrated that the ulrichINJECT CT motion is substantially equivalent to the predicate device (K210541). ulrichINJECT CT motion Traditional 510(k) Page 10 of 10
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%